Dublin, April 05, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Molecular Diagnostics - Technologies, Markets and Companies" to their offering.
This report describes and evaluates the molecular diagnostics technologies that will play an important role in practice of medicine, public health, pharmaceutical industry, forensics and biological warfare in the 21st century. This includes several polymerase chain reaction (PCR)-based technologies, fluorescent in situ hybridization (FISH), peptide nucleic acids (PNA), electrochemical detection of DNA, sequencing, mitochondrial DNA, biochips, nanotechnology and proteomic technologies.
Initial applications of molecular diagnostics were mostly for infections but are now increasing in the areas of genetic disorders, preimplantation screening and cancer. Genetic screening tests, despite some restrictions is a promising area for future expansion of in vitro diagnostic market. Molecular diagnostics is being combined with therapeutics and forms an important component of integrated healthcare. Molecular diagnostic technologies are also involved in development of personalized medicine based on pharmacogenetics and pharmacogenomics. Currently, there has been a considerable interest in developing rapid diagnostic methods for for point-of-care and biowarfare agents such as anthrax.
The number of companies involved in molecular diagnostics has increased remarkably during the past few years. More than 1,000 companies have been identified to be involved in developing molecular diagnostics and 342 of these are profiled in the report along with tabulation of 812 collaborations. Despite the strict regulation, most of the development in molecular diagnostics has taken place in the United States, which has the largest number of companies.
The markets for molecular diagnostics technologies are difficult to estimate. Molecular diagnostics markets overlap with markets for non-molecular diagnostic technologies in the in vitro diagnostic market and are less well defined than those for pharmaceuticals. Molecular diagnostic markets are analyzed for 2015 according to technologies, applications and geographical regions. Forecasts are made up to 2025. A major portion of the molecular diagnostic market can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics.
Benefits of this report
- This report has evolved during the past 20 years, profiting from feedback by numerous readers and experts.
- The most comprehensive and up-to-date one-stop source of information on technical and commercial aspects of molecular diagnostics.
- Includes profiles of 342 companies, the largest number in any report on this topic.
- 600 references, cited in the report are included in the bibliography.
- The text is supplemented by 102 tables and 15 figures.
Key Topics Covered:
Part I: Technologies & Applications
Executive Summary
1. Introduction
2. Molecular Diagnostic Technologies
3 DNA dendrimer signal amplification
3. Biochips, Biosensors, and Nanobiotechnology
4. Proteomic Technologies for Molecular Diagnostics
5. Molecular Diagnosis of Genetic Disorders
6. Molecular diagnosis of cardiovascular disorders
7. Molecular Diagnosis of Infections
8. Molecular Diagnosis of Cancer
9. Molecular Diagnostics in Biopharmaceutical Industry & Healthcare
10. Molecular Diagnostics in Forensic Medicine and Biological Warfare
11. References
Part II: Regulations, Markets & Companies
12. Ethics, Patents and Regulatory issues
13. Markets for Molecular Diagnostics
14. Companies involved in molecular diagnostics
For more information visit http://www.researchandmarkets.com/research/t3f2td/molecular
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: In Vitro Diagnostics, Molecular Diagnostics


South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 



